We assessed the effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants. Systematic search of PubMed, EMBASE and CNKI (China National Knowledge Infrastructure) databases without language restriction for studies published before 19th September, 2022. The review was registered with PROSPERO (CRD42022335430) and reported according to PRISMA guidelines. 40 studies met the inclusion criteria for this study, with 62,954,861 participates. The overall vaccine effectiveness (VE) to prevent COVID-19 infection was 0.76 (95% CI 0.73 to 0.78), symptomatic infection was 0.87 (95% CI 0.83 to 0.91), hospital admissions was 0.82 (95% CI 0.75 to 0.87), and mortality was 0.76 (95% CI 0.48 to 0.89). Subgroup analysis were performed to characterize the effectiveness of different vaccines. When SARS-CoV-2 variants are taking account, the VE decreased along with the variation of the virus by clinical outcomes and vaccine types. The findings of this systematic review provide the best available evidence that BNT162b2, mRNA-1273, ChAdOx1 and Ad26.COV2.S seems to be approximately effective from pre-delta to omicron, but only modestly effective in participates aged 65 or older. When SARS-CoV-2 variants are taking account, VE decreased along with the variation of the virus for all mRNA and viral-vector vaccines. This article is protected by copyright. All rights reserved.
- Adults
- Older adults
- Vaccine/vaccination
- Efficacy/effectiveness
- COVID-19
